195 related articles for article (PubMed ID: 31451695)
1. Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
Xiong K; Zhang H; Du Y; Tian J; Ding S
Exp Mol Med; 2019 Aug; 51(8):1-15. PubMed ID: 31451695
[TBL] [Abstract][Full Text] [Related]
2. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
4. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B
Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
Song S; Wang Y; Xu P; Yang R; Ma Z; Liang S; Zhang G
Int J Oncol; 2015 Nov; 47(5):1819-28. PubMed ID: 26412386
[TBL] [Abstract][Full Text] [Related]
7. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
8. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
11. The Ω-3 fatty acid docosahexaenoic acid selectively induces apoptosis in tumor-derived cells and suppress tumor growth in gastric cancer.
Ortega L; Lobos-González L; Reyna-Jeldes M; Cerda D; De la Fuente-Ortega E; Castro P; Bernal G; Coddou C
Eur J Pharmacol; 2021 Apr; 896():173910. PubMed ID: 33508285
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
[TBL] [Abstract][Full Text] [Related]
14. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.
Lu H; Yang XF; Tian XQ; Tang SL; Li LQ; Zhao S; Zheng HC
Oncotarget; 2016 Aug; 7(35):56508-56525. PubMed ID: 27447743
[TBL] [Abstract][Full Text] [Related]
15. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
19. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Ma Z; Liu D; Di S; Zhang Z; Li W; Zhang J; Xu L; Guo K; Zhu Y; Li X; Han J; Yan X
J Pineal Res; 2019 Sep; 67(2):e12587. PubMed ID: 31090223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
